TEAM
Felix Krenzien
Christian Benzing
Jens Lion
Bench to finance side:
We are a startup from Berlin founded by physicians and finance professionals with both tremendous scientific expertise as well as profound knowledge of financial markets. In addition to many years of work in the laboratory, we have extensive clinical experience. We have designed and conducted dozens of clinical studies, including experimental studies, observation studies as well as registration studies. We combine the fascination of science with the possibilities of asset analysis in the biotechnological field. In addition, we have been navigating equity markets with significant success due to our thorough combination of financial expertise and scientific knowledge. Our unique skill set has led to us being on the expert panel of the largest stock exchange platform in Germany for biotechnology.
BLK1 Science
is a company specialized in biotechnology that evaluates study drugs according to their stages of development. This includes a well-founded analysis of study results and places them in the context of competing drugs in development. In addition, a target market analysis with a determination of the patients in need of therapy is carried out. Furthermore, an analysis for the probability of success of a corresponding drug is carried out based on a profound analysis of previous approval studies and available preliminary data.
This is a form of investing that uses specific academic knowledge and evidence to build investment portfolios. Such an approach is particularly appropriate in the biotech sector, as drug development is based on medical evidence and elements like statistics and study design are of paramount importance. According to our experience, the stock price of a biotech companyalways reflects the success of the study. By carrying out an a priori risk analysis of the available medical data, for example from a phase II, the probability of success of a phase III can be calculated. An asset analysis is carried out on the basis of medical evidence, taking various factors into account. The asset of every biotech company is the driver for future share price developments.
BLK1 Science UG (haftungsbeschränkt)
Naumannstr. 26
DE - 10829 Berlin
Mail:
business@blk1science.com
Careers:
career@blk1-science.com
Follow us: